Preview Mode Links will not work in preview mode

Dec 29, 2021

Dear Plus Three listeners, 

 

Thanks so much for your continued support throughout the year. We couldn't do it without y'all. Psymposia is a small 501(c)(3) non-profit entirely funded by people who believe in our work. We're a volunteer organization and 100% of the funds we raise go into operating costs, which add up quickly. Please consider supporting us monthly on Patreon or making a one-time donation. All donations made by December 31st at midnight are tax-deductible. 

 

Thanks for your support! (Read Psymposia's full 2021 Year in Review with selected stories here)

 

2021 was a watershed year for psychedelics, marked by both mainstream excitement about their potential benefits alongside warning signs about the risks of harm—to both individuals and society—caused by the people who wield them.



What a wild ride it’s been. Local organizers have continued to decriminalize psychedelics throughout the United States, new research centers have been announced almost monthly, and long-overdue conversations about ethics are gaining prominence.



Despite these positive developments, there is cause for alarm. From a self-described “shaman” storming the Capitol to revelations about psychedelic therapist abuse, 2021 witnessed multiple bellwether events for psychedelic authoritarianism, which highlight the need for ongoing ideological harm reduction to protect against abuses of power.



At the same time, special interests and corporations backed by right-wing funders are trying to grab the reins and control the psychedelic narrative. We’re determined to even the playing field.

 

Through it all, Psymposia has provided unmatched reporting and analysis to challenge the polished pitches and press releases that have been disseminated by psychedelic pharma and the mainstream medicalization movements. 



Our mission is not to simply deconstruct the logic of prohibition, but to democratize access to the information we need to build a post-prohibition world that works for all of us. While psychedelic decriminalization is a positive first step, Psymposia continues to advocate for complete drug decriminalization.



Psymposia exists as a result of the relentless work that our volunteer staff pours into our projects—projects that have garnered national and international attention for our groundbreaking research and journalism. Now, more than ever, we believe in the necessity of our work, which is unfettered by the corporate payoffs, conflicts of interest, and sponsored content that have become commonplace in the field.



Psymposia is a 100% independent non-profit media and research organization that is dedicated to challenging the narratives of the powerful and of the power-seeking on behalf of the public.  



Through articles, podcasts, videos, and peer-reviewed research published in top academic journals, our team continues to impact the conversation about psychedelics and drug policy—despite repeated industry efforts to silence us and marginalize our work.



But in order to do our work as a watchdog, your financial support is vital.Unlike other media outlets covering psychedelics and drug policy, we refuse to compromise our mission or create conflicts of interest by accepting funding from the corporations we are tasked with covering. 



While other psychedelics organizations have blacklisted us and threatened to doxx our sources, we are unapologetic about our work and stand by our mission.



We are sustained by people and communities who believe in the work we do. You can support us monthly on Patreon or make a one-time donation (and, until Friday at midnight, donations are still tax-deductible for 2021). 



If you’re unable to donate, you can support us in other ways, like sharing an article with a friend, leaving our podcasts a rating and review, or simply sending us a message. We appreciate the non-monetary support and solidarity we've received this year. It means a lot to us.



Thank you for your continued support. 



In solidarity, 

The Psymposia team

 

Subscribe to the Psymposia email list here